B-intervention	0	6	Racial
I-intervention	7	18	differences
O	19	21	in
O	22	30	clinical
O	31	39	outcomes
O	40	44	from
O	45	55	metastatic
O	56	62	breast
O	63	69	cancer
O	69	70	:
O	71	72	a
O	73	79	pooled
O	80	88	analysis
O	89	91	of
O	92	97	CALGB
O	98	102	9342
O	103	106	and
O	107	111	9840
O	111	112	-
O	112	113	-
O	113	119	Cancer
O	120	123	and
O	124	132	Leukemia
O	133	138	Group
O	139	140	B
O	140	141	.
O	142	149	African
O	150	158	American
O	159	164	women
O	165	168	are
O	169	173	more
O	174	180	likely
O	181	183	to
O	184	186	be
O	187	196	diagnosed
O	197	201	with
O	202	212	metastatic
O	213	219	breast
O	220	226	cancer
O	227	229	at
O	230	233	the
O	234	238	time
O	239	241	of
O	242	254	presentation
O	255	259	than
O	260	266	whites
O	266	267	,
O	268	271	and
O	272	276	have
O	277	284	shorter
O	285	293	survival
O	294	298	once
O	299	308	diagnosed
O	308	309	.

O	310	314	This
O	315	320	study
O	321	329	examines
O	330	336	racial
O	337	348	differences
O	349	351	in
O	352	360	clinical
O	361	369	outcomes
O	370	372	in
O	373	376	the
O	377	384	setting
O	385	387	of
O	388	391	two
O	392	397	large
O	398	409	cooperative
O	410	415	group
O	416	426	randomized
O	427	435	clinical
O	436	442	trials
O	442	443	.

O	444	447	The
O	448	453	study
O	454	460	cohort
O	461	470	consisted
O	471	473	of
B-intervention-participants	474	477	787
B-intervention	478	483	white
O	484	485	(
O	485	487	80
O	487	488	%
O	488	489	)
O	490	493	and
B-control-participants	494	497	195
B-control	498	505	African
I-control	506	514	American
O	515	516	(
O	516	518	20
O	518	519	%
O	519	520	)
B-eligibility	521	529	patients
I-eligibility	530	534	with
I-eligibility	535	545	metastatic
I-eligibility	546	552	breast
I-eligibility	553	559	cancer
O	560	568	enrolled
O	569	571	in
O	572	575	two
O	576	586	successive
O	587	593	Cancer
O	594	597	and
O	598	606	Leukemia
O	607	612	Group
O	613	614	B
O	615	616	(
O	616	621	CALGB
O	621	622	)
O	623	629	trials
O	630	635	using
O	636	643	taxanes
O	644	646	in
O	647	650	the
O	651	661	metastatic
O	662	669	setting
O	669	670	.

O	671	682	Differences
O	683	685	in
O	686	693	overall
O	694	702	survival
O	703	704	(
O	704	706	OS
O	706	707	)
O	707	708	,
O	709	717	response
O	718	727	incidence
O	727	728	,
O	729	732	and
O	733	737	time
O	738	740	to
O	741	750	treatment
O	751	758	failure
O	759	760	(
O	760	763	TTF
O	763	764	)
O	765	769	were
O	770	778	examined
O	779	781	by
O	782	786	race
O	786	787	.

O	788	790	In
O	791	799	addition
O	799	800	,
O	801	812	differences
O	813	815	in
O	816	819	the
O	820	829	incidence
O	830	832	of
O	833	841	baseline
O	842	845	and
O	846	855	treatment
O	855	856	-
O	856	863	related
O	864	874	toxicities
O	875	879	were
O	880	888	examined
O	888	889	.

O	890	894	With
O	895	898	779
B-outcome	899	905	deaths
O	906	907	(
B-cv-bin-abs	907	910	166
O	911	918	African
O	919	928	Americans
O	929	932	and
B-iv-bin-abs	933	936	613
O	937	943	whites
O	943	944	)
O	944	945	,
B-outcome	946	952	median
I-outcome	953	955	OS
O	956	959	was
B-cv-cont-median	960	962	14
I-cv-cont-median	962	963	.
I-cv-cont-median	963	964	3
I-cv-cont-median	965	971	months
O	972	975	for
O	976	983	African
O	984	993	Americans
O	994	997	and
B-iv-cont-median	998	1000	18
I-iv-cont-median	1000	1001	.
I-iv-cont-median	1001	1003	75
I-iv-cont-median	1004	1010	months
O	1011	1014	for
O	1015	1021	whites
O	1022	1023	(
O	1023	1029	hazard
O	1030	1035	ratio
O	1036	1037	[
O	1037	1039	HR
O	1039	1040	]
O	1041	1042	=
O	1043	1044	1
O	1044	1045	.
O	1045	1047	37
O	1047	1048	;
O	1049	1051	95
O	1051	1052	%
O	1053	1055	CI
O	1055	1056	,
O	1057	1058	1
O	1058	1059	.
O	1059	1061	15
O	1062	1064	to
O	1065	1066	1
O	1066	1067	.
O	1067	1069	63
O	1069	1070	)
O	1070	1071	.

O	1072	1076	When
O	1077	1085	adjusted
O	1086	1089	for
O	1090	1100	prognostic
O	1101	1108	factors
O	1108	1109	,
O	1110	1117	African
O	1118	1127	Americans
O	1128	1131	had
O	1132	1133	a
O	1134	1136	24
O	1136	1137	%
O	1138	1146	increase
O	1147	1149	in
O	1150	1153	the
B-outcome	1154	1160	hazard
I-outcome	1161	1163	of
I-outcome	1164	1169	death
O	1170	1178	compared
O	1179	1183	with
O	1184	1190	whites
O	1191	1192	(
O	1192	1194	HR
O	1195	1196	=
O	1197	1198	1
O	1198	1199	.
O	1199	1201	24
O	1201	1202	;
O	1203	1205	95
O	1205	1206	%
O	1207	1209	CI
O	1209	1210	,
O	1211	1212	1
O	1212	1213	.
O	1213	1215	02
O	1216	1218	to
O	1219	1220	1
O	1220	1221	.
O	1221	1223	51
O	1223	1224	)
O	1224	1225	.

O	1226	1228	No
O	1229	1240	significant
O	1241	1252	differences
O	1253	1255	in
B-outcome	1256	1259	TTF
I-outcome	1260	1262	or
I-outcome	1263	1270	overall
I-outcome	1271	1279	response
O	1280	1282	to
O	1283	1290	therapy
O	1291	1295	were
O	1296	1300	seen
O	1300	1301	.

O	1302	1304	No
O	1305	1315	clinically
O	1316	1327	significant
B-outcome	1328	1336	toxicity
O	1337	1348	differences
O	1349	1353	were
O	1354	1358	seen
O	1358	1359	.

O	1360	1367	African
O	1368	1377	Americans
O	1378	1382	with
O	1383	1393	metastatic
O	1394	1400	breast
O	1401	1407	cancer
O	1408	1412	have
O	1413	1415	an
O	1416	1425	increased
B-outcome	1426	1432	hazard
I-outcome	1433	1435	of
I-outcome	1436	1441	death
O	1442	1450	compared
O	1451	1455	with
O	1456	1462	whites
O	1463	1470	despite
O	1471	1474	the
O	1475	1482	receipt
O	1483	1485	of
O	1486	1493	similar
O	1494	1497	per
O	1497	1498	-
O	1498	1506	protocol
O	1507	1516	treatment
O	1516	1517	,
O	1518	1521	but
O	1522	1532	experience
O	1533	1535	no
O	1536	1547	differences
O	1548	1550	in
O	1551	1554	TTF
O	1555	1557	or
O	1558	1565	overall
O	1566	1574	response
O	1575	1577	to
O	1578	1585	therapy
O	1585	1586	.

O	1587	1589	We
O	1590	1601	hypothesize
O	1602	1606	that
O	1607	1611	more
O	1612	1618	direct
O	1619	1622	and
O	1623	1629	robust
O	1630	1638	measures
O	1639	1641	of
O	1642	1655	comorbidities
O	1655	1656	,
O	1657	1660	and
O	1661	1668	perhaps
O	1669	1674	other
O	1675	1682	factors
O	1683	1687	such
O	1688	1690	as
O	1691	1698	receipt
O	1699	1701	of
O	1702	1712	subsequent
O	1713	1720	therapy
O	1721	1726	could
O	1727	1731	help
O	1732	1739	further
O	1740	1747	explain
O	1748	1751	the
O	1752	1760	observed
O	1761	1769	survival
O	1770	1780	difference
O	1780	1781	.
